Stock Comparison

LLY vs RXRX

Eli Lilly and Co vs Recursion Pharmaceuticals Inc

The Verdict

RXRX takes this one.

LLY

Eli Lilly and Co

0.5

out of 10

Distressed

Winner

RXRX

Recursion Pharmaceuticals Inc

7.3

out of 10

Solid Pick

Head-to-Head

$965.0B

Market Cap

$1.9B

52.6

P/E Ratio

N/A

Profit Margin

-863.4%

N/A

Return on Equity

-64.0%

N/A

Debt-to-Equity

0.0

Moderate

Overall Risk

Aggressive investment

0.5

DVR Score

7.3

The Deep Dive

LLY0.5/10

Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achiev...

Full LLY Analysis

RXRX7.3/10

Recursion Pharmaceuticals (RXRX) maintains significant long-term disruptive potential with its AI/ML Biofoundry and key partnerships. The recent Q4 2025 EPS beat (-$0.20 vs. -$0.30 consensus) indicates some operational efficiency gains. More importantly, positive Phase 1b/2 TUPELO data for REC-4881 (FAP) and BlackRock's increased 7.2% stake are strong positive catalysts and institutional endorseme...

Full RXRX Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.